An update from Kintara Therapeutics (KTRA) is now available.
Kintara Therapeutics, Inc. is set to acquire TuHURA Biosciences, Inc., with the merger expected to conclude in the third quarter of 2024, transforming TuHURA into a direct, wholly-owned subsidiary of Kintara. This strategic move will see TuHURA shareholders owning a significant majority of the combined company, while Kintara shareholders will retain a smaller portion. The deal hinges on various conditions, including stockholder approvals and regulatory clearances, with a comprehensive integration plan involving executive and board-level changes. Kintara has also issued bonuses to its CEO and resumed payment of deferred directors’ fees. Additional details and discussions on the merger will be shared in an upcoming joint conference call and investor presentation.
Find detailed analytics on KTRA stock on TipRanks’ Stock Analysis page.
